Wolfe Research upgraded Abbott Laboratories to Peer Perform from Underperform without a price target. The company’s Q2 report “substantially reduces” concerns about the core ramp required to hit its 2023 profit guidance, the analyst tells investors in a research note. The firm set a new fair value range of $107-$112 for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott (NYSE: ABT) Stock Gains on Q2 Beat; Lifts 2023 Revenue Forecast
- Abbott saw ‘very strong growth’ across all four sectors in Q2
- Abbott sees Q3 adjusted EPS about $1.10, consensus $1.11
- Abbott reports Q2 worldwide Medical Devices sales up 13.5% on reported basis
- Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business